Why Isis Pharmaceuticals Continues to Impress

Isis may not be profitable yet, but its RNA antisense discovery platform continues to churn out viable drug candidates.

Mar 5, 2014 at 2:30PM

Over the past twelve months Isis Pharmaceuticals (NASDAQ:ISIS) has been on a tear both at the deal table and in the market. At $51, Isis is still up more than 230% over the past twelve months. The company reported fourth quarter 2013 earnings on February 28 before the market opened. The bottom line came in just $0.01 lower than estimates at a loss of $0.21 per share. On top, Isis reported revenue of $42.2 million, about $8 million above estimates.

Apparently the Street expected better and the stock finished the day down 9.5%. The biggest complaint was a lack of info concerning Kynamro sales and a fourth quarter loss that grew from $2.6 million in 2012, to $24.3 million last year.

While the widening loss in the fourth quarter might seem drastic, milestone payments and other irregular cash flows often result in erratic swings for this company. Smoothing the figures out over twelve months tells a different story. For the entire year of 2013, Isis lost just $60.6 million compared to $65.5 million in 2012.

The reason the company's annual loss shrank about 7.5% last year was an increase in revenue from partnerships, of which Isis has many. FDA approval of the company's lead program, Kynamro for the treatment of homozygous familial hypercholesterolemia (HoFH) in January 2013, went a long way to generate interest in the company's RNA antisense drug discovery platform.

Not a big seller
Unfortunately, Kynamro sales haven't added much to the company's top line in its first year on the market. The drug was developed and commercialized in partnership with Sanofi's (NYSE:SNY) subsidiary Genzyme. Despite the approval, revenue from the Genzyme agreement is shrinking. During 2013, 2012, and 2011, Isis earned revenue of $32.5 million, $67.6 million, and $72.3 million, respectively, from Genzyme. Isis reported overall revenue from licensing activities and royalties of $3.1 million for 2013, compared to $5.6 million for 2012.

Kynamro is approved for an extremely limited indication. The frequency of HoFH is a subject of heated debate, but it is low. Prior to the existence of an effective therapy the generally accepted frequency was about one person in 1,000,000. As is often the case with orphan diseases, the emergence of an effective treatment may bring patients out of the woodwork. Whatever the size of the US HoFH population, Isis and Genzyme are sharing it with Aegerion Pharmaceuticals (NASDAQ:AEGR) and its therapy, lomitapide. Aegerion reported 430 US patients on therapy at the end of 2013.

Genzyme and Isis will most likely not be competing with Aegerion for HoFH patients in the EU. The European Medicines Agency Committee for Medicinal Products for Human Use recommended against Kynamro's approval, twice. The agency cited a high rate of discontinuation due to side effects, and cardiovascular events.

An efficient discovery platform
Isis probably won't earn a great deal in royalties from its first approved product. That's hardly a reason to avoid the company. It finished 2013 with a staggering 31 compounds in development. The company is conducting more than 20 trials. With less than 400 employees, the company's pipeline is large enough to make a drug major jealous.

Lots of partners
Of course, Isis isn't developing all of these compounds on its own. The company is advancing most of its drugs through a series of partnerships. Last year the company earned about one fifth of its total revenue from a partnership with AstraZeneca (NYSE: AZN), which is picking up the tab for most of the clinical development costs of several compounds. In return, Isis may receive more than $1.1 billion in milestone payments, plus double-digit royalties should any reach a commercial stage. Isis has also teamed up with Biogen Idec (NASDAQ:BIIB) in four separate partnerships. These partnerships span drugs for a variety of indications, including spinal muscular atrophy and myotonic dystrophy .

Final take
Kynamro might not be going anywhere fast, and that's fine. Isis' discovery platform has been very efficient at getting candidates into the clinic. Deep pocketed pharmaceutical heavyweights are lining up to assume the risk of developing many of them. This company has initiated more than 20 trials with its limited staff. Thinking ahead, imagine what it can accomplish with a Big Pharma-sized stable of researchers.

Thinking ahead even further
It's no secret that investors tend to be impatient with the market, but the best investment strategy is to buy shares in solid businesses and keep them for the long term. In the special free report "3 Stocks That Will Help You Retire Rich," The Motley Fool shares investment ideas and strategies that could help you build wealth for years to come. Click here to grab your free copy today.

Cory Renauer owns shares of Aegerion Pharmaceuticals. The Motley Fool recommends Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information

Compare Brokers